$IRON (DISC MEDICINE) — 8-K: DISC-3405 Phase 2 RESTORE-PV data show reduced phlebotomy and controlled hematocrit in PV

Initial results from the 40-patient RESTORE-PV trial showed DISC-3405 increased hepcidin and lowered serum iron. In Cohort A, mean hematocrit was maintained stably below 45% through week 26, with improved symptom burden. For 13 patients completing 26 weeks, DISC-3405 significantly reduced phlebotomy events.

Initial results from the 40-patient RESTORE-PV trial showed DISC-3405 increased hepcidin and lowered serum iron. In Cohort A, mean hematocrit was maintained stably below 45% through week 26, with impr